Hologic, Inc. (NASDAQ:HOLX) Stake Decreased by Davis R M Inc.

Davis R M Inc. lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 12.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,348 shares of the medical equipment provider’s stock after selling 739 shares during the period. Davis R M Inc.’s holdings in Hologic were worth $417,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in HOLX. McGlone Suttner Wealth Management Inc. bought a new stake in Hologic during the fourth quarter worth approximately $27,000. Allworth Financial LP raised its holdings in Hologic by 39.3% during the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 179 shares in the last quarter. Mather Group LLC. bought a new stake in Hologic during the first quarter worth approximately $48,000. Massmutual Trust Co. FSB ADV raised its holdings in Hologic by 24.7% during the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 137 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt raised its holdings in Hologic by 145.3% during the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 468 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Insider Activity at Hologic

In related news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the transaction, the director now directly owns 45,472 shares in the company, valued at $3,615,024. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. 1.75% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on HOLX shares. Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Hologic in a report on Friday, May 3rd. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Stephens began coverage on shares of Hologic in a research report on Thursday, June 27th. They issued an “overweight” rating and a $87.00 price target on the stock. Evercore ISI decreased their price target on shares of Hologic from $78.00 to $76.00 and set an “in-line” rating on the stock in a research report on Tuesday, July 2nd. Finally, Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.55.

Hologic Stock Down 0.2 %

Shares of HOLX stock traded down $0.14 on Tuesday, hitting $78.24. The company’s stock had a trading volume of 423,774 shares, compared to its average volume of 1,612,802. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $82.45. The firm’s fifty day moving average price is $74.31 and its 200-day moving average price is $74.85. The stock has a market capitalization of $18.26 billion, a price-to-earnings ratio of 39.85, a P/E/G ratio of 2.60 and a beta of 0.99.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.05. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter in the previous year, the business earned $1.06 EPS. Hologic’s quarterly revenue was down .8% compared to the same quarter last year. Research analysts anticipate that Hologic, Inc. will post 4.08 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.